Opioid Drugs

Daiichi increases efforts to break into opioid market

Daiichi increases efforts to break into opioid market

By

The drugmaker is collaborating with Charleston Laboratories in the development and commercialization of hydrocodone products. The deal means Daiichi Sankyo now has two pipeline opiates.

Zohydro to get marketing overhaul

Zohydro to get marketing overhaul

By

The painkiller's marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.

Purdue pain drug gets priority status

Purdue pain drug gets priority status

By

Purdue Pharma expects the FDA to vote yea or nay on the drug by October.

CDC: US is biggest Rx opioid market

CDC: US is biggest Rx opioid market

By

The Centers of Disease Control reports that prescribers wrote enough painkiller prescriptions to give one bottle to every adult in the US in 2012.

Seniors are major painkiller users

A USA today analysis shows Medicare painkiller prescriptions rose 30% between 2007 and 2012.

FDA standing by its Zohydro approval

FDA standing by its Zohydro approval

By

The regulator defends its approval decision in a web post.

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Massachusetts bans Zohydro

The Bay State is saying no to the controversial prescription painkiller.

Senator seeks anti-Zohydro legislation

West Virginia's Joe Manchin has sponsored a bill to push pain medication Zohydro off the FDA's approval list.

Doctors, not friends, source of many opioids

A study says that more opioid abusers get their medications via prescription than they do second-hand.

Zohydro opposition ramps up

A group called the FED up! Coalition has sent a letter to FDA Commissioner Margaret Hamburg, urging her to overturn the approval.

Judge: Teva not liable for Oxycontin patent violation

Purdue Pharma says it will appeal.

28 attorneys general say no to Zohydro

State legal reps ask Commissioner Hamburg to overturn the approval.

Business briefs: inVentiv, Novo, Bayer, Purdue

inVentiv launches new policy shop; early test shows Novo's Victoza may have Alzheimer's future; Bayer joins the list of China's scrutinized pharma companies; a Chicago bar gives Purdue unwanted attention

FDA tightens indication and label for opioid sub-category

FDA tightens indication and label for opioid sub-category

By

The changes, which include tightening prescribing criteria of extended-release and long-acting opioids and a boxed warning for pregnancy, are part of an effort to curb abuse. Some said the FDA's effort is too limited

Acura's abuse-deterrent painkiller fails to displease

By

Phase II studies found recreational abusers were not significantly bothered by the mechanism meant to make a "deterrent" version unpleasant to snort.

CVS joins prescription crackdown

By

The drugstore chain says it has cut off over-prescribers of tightly controlled medications.

J&J painkiller probe expands scrutiny of industry marketing

By

HHS is looking into how J&J marketed opioid painkiller Nucynta, adding to the firm's list of investigations and those of the industry as a whole.

Actavis gets go-ahead to expand generic painkiller portfolio

By

The drug maker can now add five new doses to its generic Opana ER offerings.

Business Briefs: India Health Ministry, Takeda, Sucampo and Pfizer Consumer Care

India bans sales of Takeda's Actos; Takeda make a $10-million milestone payment to Sucampo; and Pfizer Consumer Care says Advil is the official pain reliever of Tough Mudder.

FDA move gives Purdue edge in painkiller market

FDA move gives Purdue edge in painkiller market

By

Generic Opana ER got the go-ahead from FDA, exposing the drugmaker to generic competition -- unlike Purdue, whose tamper-proof painkiller won standalone status.

Email Newsletters

MM&M inVISION